---
title: "Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289224546.md"
description: "Gilead and Merck discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial for Trodelvy plus Keytruda in lung cancer due to lack of statistical significance in progression-free survival. Separately, they reported positive Phase 3 results for an investigational once-weekly oral HIV regimen combining islatravir and lenacapavir, which met primary efficacy endpoints. Regulatory filings are planned for the HIV treatment."
datetime: "2026-06-09T17:44:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289224546.md)
  - [en](https://longbridge.com/en/news/289224546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289224546.md)
---

# Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

On Monday, **Gilead Sciences Inc.** (NASDAQ:GILD) and **Merck & Co. Inc.** (NYSE:MRK) on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda in previously untreated metastatic non-small cell lung cancer with high PD-L1 expression, following a Data Monitoring Committee review of progression-free survival and interim overall survival data.

While the combo showed a numerical improvement in progression-free survival, it did not reach statistical significance, and investigators said the probability of achieving a meaningful overall survival benefit at final analysis was low. Safety remained consistent with known profiles, with no new signals identified. Full data will be presented at a future medical meeting.

Separately, the companies reported positive Phase 3 results for an investigational once-weekly oral HIV regimen combining islatravir and lenacapavir, which met its primary efficacy endpoint in two studies.

**Read Also: Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst**

## Once-Weekly HIV Regimen Meets Late-Stage Trial Goals

The Phase 3 ISLEND-1 and ISLEND-2 trials evaluated the safety and efficacy of the oral single-tablet regimen in people living with HIV who were already virologically suppressed.

According to the companies, the primary endpoint in both studies measured the percentage of participants with HIV-1 RNA levels of at least 50 copies/mL at Week 48 under the FDA snapshot algorithm.

In the ISLEND-1 study, patients switched from Biktarvy to the once-weekly islatravir/lenacapavir regimen. The treatment was found to be statistically non-inferior to Biktarvy.

Meanwhile, in the open-label ISLEND-2 trial, the regimen demonstrated statistical non-inferiority compared with standard-of-care daily oral antiretroviral therapies.

The companies said the safety profile of the combination was generally comparable to the comparator regimens in both studies, with no new safety concerns identified.

## Regulatory Filings Planned Following HIV Results

Gilead and Merck said they plan to submit the Phase 3 findings to regulatory authorities worldwide and present detailed data at a future scientific congress.

The investigational combination targets multiple stages of HIV-1 replication. If approved, the treatment could offer virologically suppressed patients a long-acting, once-weekly oral single-tablet option.

**GILD and MRK Stock Price Activity**: Gilead Sciences shares were down 2.28% at $125.18, and Merck shares were up 0.46% at $120.07 at the time of publication on Tuesday, according to Benzinga Pro data.

**Read Also: Institutions Are Choosing Sides – What the ETF Data Says About Ethereum Vs. Solana**

_Photo by Sundry Photography via Shutterstock_

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [TERN.US](https://longbridge.com/en/quote/TERN.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess](https://longbridge.com/en/news/288833431.md)
- [Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa | GILD Stock News](https://longbridge.com/en/news/288820076.md)
- [Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study | MRK Stock News](https://longbridge.com/en/news/289100847.md)
- [Gilead And Lakefront Acquire Ouro Medicines In $1.67 Bln Agreement; To Co-Develop Gamgertamig](https://longbridge.com/en/news/288851463.md)
- [Calderasib–Keytruda Breakthrough Therapy Status Might Change The Case For Investing In Merck (MRK)](https://longbridge.com/en/news/288791626.md)